Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Two-year Study to Determine the Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis for 2 Years Followed by a 2 Year Open Label Study

NCT00619957 is registered in ClinicalTrials.gov with Warner Chilcott as lead sponsor.

NCT NCT00619957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00619957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Two-year Study to Determine the Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis for 2 Years Followed by a 2 Year Open Label Study
Lead sponsor
Warner Chilcott
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2002
Completion date
May 31, 2007
Enrollment
285 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

other osteoporosis